RRAS2 and breast cancer: Moreover, a polymorphism in the RRAS2 promoter is associated with an unfavorable tamoxifen treatment outcome [33], and silencing the RRAS2 gene enhances the tamoxifen sensitivity of a BC cell line [34], indicating RRAS2 is an important gene in the development and clinical outcome of BC.